Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade-Reference-Cited by-同舟云学术

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade

Published:2019-08-29 Issue:17 Volume:134 Page:1406-1414
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rauch Daniel A.¹,Conlon Kevin C.²,Janakiram Murali³,Brammer Jonathan E.⁴,Harding John C.¹,Ye B. Hilda⁵,Zang Xingxing³⁶,Ren Xiaoxin⁶,Olson Sydney¹^ORCID,Cheng Xiaogang¹,Miljkovic Milos D.²^ORCID,Sundaramoorthi Hemalatha¹,Joseph Ancy¹,Skidmore Zachary L.¹,Griffith Obi¹^ORCID,Griffith Malachi¹,Waldmann Thomas A.²,Ratner Lee¹

Affiliation:

1. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO;

2. Lymphoid Malignancies Branch, National Institutes of Health, Bethesda, MD;

3. Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY;

4. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH; and

5. Department of Cell Biology and

6. Department of Microbiology and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

Abstract

The investigators present their analysis of primary cells from patients with human T-cell leukemia virus 1–associated adult T-cell leukemia/lymphoma treated in a phase 2 clinical trial with nivolumab to elucidate mechanisms of hyperprogression that halted the trial after just 3 patients received a single treatment.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/17/1406/1502414/bloodbld2019002038.pdf

Reference45 articles.

1. Cancer immunotherapy: harnessing the immune system to battle cancer;Yang;J Clin Invest,2015

2. Cancer immunotherapy: a review;Meiliana;Indones Biomedical Journal,2016

3. Cancer immunotherapy: the beginning of the end of cancer?;Farkona;BMC Med,2016

4. Hyperprogressive disease: recognizing a novel pattern to improve patient management;Champiat;Nat Rev Clin Oncol,2018

5. Hyperprogression as a distinct outcome after immunotherapy;Fuentes-Antrás;Cancer Treat Rev,2018

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma;Journal of Experimental & Clinical Cancer Research;2024-09-14

2. Development of Subcutaneous Panniculitis-Like T-cell Lymphoma After Immune Checkpoint Inhibitor Treatment;Cureus;2024-08-15

3. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study;Signal Transduction and Targeted Therapy;2024-05-17

4. Decrease and impaired function of circulating mucosa-associated invariant T cells in acute myeloid leukemia;2024-03-28

5. A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma;Leukemia & Lymphoma;2024-03-09